Trinity Delta view: Arecor’s formulation expertise underpins both the in-house clinical pipeline and the partnered Specialty Hospital Products programmes. Investor attention is understandably focused on the diabetes franchise, hence the upcoming AT278 Phase I data are eagerly anticipated. Although still at the earliest stages, this partnership with TRx Biosciences for an oral GLP-1 product not only addresses a highly commercially attractive segment but, if successful, could provide complementary approaches that broaden Arecor’s formulation expertise to oral delivery. Our valuation, based on conservative assumptions, is £179m, equivalent to 583p per share.
![working](/images/WorkingLarge.gif)
13 Mar 2024
Trinity Delta Lighthouse: Arecor Therapeutics
![](/images/orange-lock.png)
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Trinity Delta Lighthouse: Arecor Therapeutics
Arecor Therapeutics PLC (AREC:LON) | 92.5 0 0.0% | Mkt Cap: 28.3m
- Published:
13 Mar 2024 -
Author:
Franc Gregori | Lala Gregorek | Philippa Gardner -
Pages:
2 -
Trinity Delta view: Arecor’s formulation expertise underpins both the in-house clinical pipeline and the partnered Specialty Hospital Products programmes. Investor attention is understandably focused on the diabetes franchise, hence the upcoming AT278 Phase I data are eagerly anticipated. Although still at the earliest stages, this partnership with TRx Biosciences for an oral GLP-1 product not only addresses a highly commercially attractive segment but, if successful, could provide complementary approaches that broaden Arecor’s formulation expertise to oral delivery. Our valuation, based on conservative assumptions, is £179m, equivalent to 583p per share.